Lotus Eye Hospital and Institute Analyst Review May 2026

This Lotus Eye Hospital and Institute analyst review for May 2026 covers all critical data investors need for LOTUSEYE at Rs 115. Lotus Eye Hospital and Institute is a chain of eye care hospitals. This Lotus Eye Hospital and Institute analyst review analyses technical levels, business fundamentals, valuation, and key risks for LOTUSEYE through FY27.

Click Here – Get Free Investment Predictions

Lotus Eye Hospital and Institute Analyst Review: Company Snapshot May 2026

Lotus Eye Hospital provides cataract, LASIK, glaucoma, and retina care services across Tamil Nadu and South India. The table below summarises key metrics for this Lotus Eye Hospital and Institute analyst review.

Parameter	Value
NSE Ticker	LOTUSEYE
Sector	Healthcare – Eye Care
CMP (May 2026)	Rs 115
52 Week High	Rs 129
52 Week Low	Rs 105
Market Cap	Rs 700 Crore
Trailing P/E	35x
Analyst Consensus Target	Rs 143.75
Bull Case Target	Rs 178.25
Bear Case Target	Rs 97.75

Analyst Insight: Lotus Eye Hospital and Institute Analyst Review for FY27

Senior Research Analyst Ankit Jaiswal flags Lotus Eye Hospital and Institute as a stock to watch in May 2026. At Rs 115, Ankit Jaiswal identifies key support in the Rs 107.10 to Rs 109.25 band and resistance near Rs 121.90. He suggests watching Lotus Eye Hospital and Institute for a potential move toward Rs 143.75. Ankit Jaiswal’s view in this Lotus Eye Hospital and Institute analyst review does not constitute a trade recommendation.

Technical Analysis in This Lotus Eye Hospital and Institute Analyst Review

This Lotus Eye Hospital and Institute analyst review places LOTUSEYE at Rs 115 within its 52-week band of Rs 105 to Rs 129. The 14-day RSI, MACD signal, and volume profile are key technical inputs when evaluating LOTUSEYE.

The Lotus Eye Hospital and Institute analyst review identifies support in the Rs 107.10 to Rs 109.25 range and resistance in the Rs 121.90 to Rs 129.38 zone. A sustained close above Rs 121.90 could signal momentum toward the analyst consensus target of Rs 143.75.

Screen the best stocks on the Univest Screener.

Support and Resistance in This Lotus Eye Hospital and Institute Analyst Review

• Support Zone: Rs 107.10 to Rs 109.25 – this Lotus Eye Hospital and Institute analyst review identifies this as a potential accumulation signal for LOTUSEYE.
• Resistance Zone: Rs 121.90 to Rs 129.38 – the Lotus Eye Hospital and Institute analyst review flags a close above Rs 121.90 as a positive signal for LOTUSEYE.
• Consensus Target: Rs 143.75 is the base-case target in this Lotus Eye Hospital and Institute analyst review.

Business Segments in This Lotus Eye Hospital and Institute Analyst Review

Cataract and Refractive Surgery

This primary segment drives revenue and margin for Lotus Eye Hospital and Institute, supporting the earnings trajectory toward Rs 143.75 in this Lotus Eye Hospital and Institute analyst review.

Glaucoma and Retina Treatments

This segment adds meaningful scale to Lotus Eye Hospital and Institute’s model and is a key EPS contributor through FY27 as identified in this Lotus Eye Hospital and Institute analyst review.

New Hospital Additions

This growth frontier is a potential re-rating catalyst for LOTUSEYE and a key element of this Lotus Eye Hospital and Institute analyst review.

Valuation: Lotus Eye Hospital and Institute Analyst Review Bull Bear Base Case

At Rs 115 and P/E of 35x, this Lotus Eye Hospital and Institute analyst review sets three scenarios: bull case Rs 178.25, base case Rs 143.75, and bear case Rs 97.75.

Scenario	Target Price	Key Condition
Bull Case	Rs 178.25	Strong FY27 delivery and Healthcare – Eye Care re-rating
Base Case	Rs 143.75	Moderate growth per analyst consensus in this Lotus Eye Hospital and Institute analyst review
Bear Case	Rs 97.75	Earnings miss or macro headwinds for LOTUSEYE

FY27 Outlook in This Lotus Eye Hospital and Institute Analyst Review

This Lotus Eye Hospital and Institute analyst review for FY27 is constructive provided LOTUSEYE delivers on earnings expectations. Q1 FY27 results will be the first checkpoint. Investors should monitor Healthcare – Eye Care indicators, RBI policy, and FII flow trends.

Key Risks in This Lotus Eye Hospital and Institute Analyst Review

This Lotus Eye Hospital and Institute analyst review identifies four key risks for LOTUSEYE: macro slowdown, input cost pressure, FII selling, and Q1 FY27 earnings disappointment.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Lotus Eye Hospital and Institute Analyst Review Verdict May 2026

This Lotus Eye Hospital and Institute analyst review concludes that LOTUSEYE at Rs 115 presents a defined risk-reward with consensus target Rs 143.75. The 52-week range of Rs 105 to Rs 129 provides further context. Use this Lotus Eye Hospital and Institute analyst review as a research reference and consult a SEBI-registered advisor before investing in LOTUSEYE.

FAQs: Lotus Eye Hospital and Institute Analyst Review 2026

What is the analyst target for Lotus Eye Hospital and Institute in 2026?

The Lotus Eye Hospital and Institute analyst review consensus target is Rs 143.75, bull case Rs 178.25, bear case Rs 97.75.

Is Lotus Eye Hospital and Institute a good buy at Rs 115?

At Rs 115 with PE 35x and target Rs 143.75, this Lotus Eye Hospital and Institute analyst review is constructive for 12-month investors. Consult a SEBI-registered advisor before acting on this Lotus Eye Hospital and Institute analyst review.

What is the 52-week high and low of Lotus Eye Hospital and Institute?

52-week high is Rs 129 and 52-week low is Rs 105. This Lotus Eye Hospital and Institute analyst review contextualises LOTUSEYE at Rs 115 within this range.

What are the key risks for Lotus Eye Hospital and Institute?

Key risks in this Lotus Eye Hospital and Institute analyst review: macro slowdown, input cost pressure, FII selling, and competitive pressure in the Healthcare – Eye Care sector.

Where can I track live data for Lotus Eye Hospital and Institute?

Track Lotus Eye Hospital and Institute’s live price on the Univest Screener to complement this Lotus Eye Hospital and Institute analyst review with real-time data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.